H.C. Wainwright analyst Sean Lee assumed coverage of Senseonics (SENS) with a Buy rating and $1.10 price target The company has the only 365-day continuous glucose monitoring system on the market, the analyst tells investors in a research note. The firm says Senseonics is believed to be the fourth largest provider of continuous glucose monitoring systems in the U.S. The company’s flagship product is Eversense 365, which is the first and so far only approved CGM system that lasts for 12 months, compared to 7-15 days for traditional CGMs, contends H.C. Wainwright.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SENS: